Proportion of participants with adverse events at 4 to 8 weeks Assessed by outcome assessors · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
Complications
Postoperative parenteral nutrition may leads to higher complications compared with oral nutrition alone (low certainty).
1 finding from 1 review
Length of hospital stay
1 finding from 1 review
All‐cause mortality
It is very uncertain whether postoperative parenteral nutrition changes mortality compared with oral nutrition alone (very low certainty).
1 finding from 1 review
The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with conventional medicine alone (low certainty).
1 finding from 1 review
QoL · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to higher qoL (EORTC QLQ‐c30) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Patient‐reported symptom: nausea/vomiting (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to lower patient‐reported symptom: nausea/vomiting (WHO grade 3 to 4) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Diarrhoea · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in patient‐reported symptom: diarrhoea compared with conventional medicine alone (low certainty).
1 finding from 1 review
Time to recurrence
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with TURBT alone (moderate certainty).
1 finding from 1 review
Time to progression
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with TURBT alone (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
1 finding from 1 review
Disease‐specific survival
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with TURBT alone (moderate certainty).
1 finding from 1 review
Disease‐specific quality of life ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported pain relief of 30% or greater · adults with fibromyalgia
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Patient Global Impression of Change much or very much improved · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
PGIC very much improved · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Access thrombosis/vascular complication · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
Scheduled surveillance showed no clear difference in risk of access thrombosis compared with clinical monitoring alone (moderate certainty).
1 finding from 1 review
Rate of angiograms · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
Scheduled surveillance may leads to higher rate of angiograms compared with clinical monitoring alone (low certainty).
1 finding from 1 review